Q-omics provides the consensus-scored CRHR1 profile across patient tissues and cancer cell-line models. CRHR1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CRHR1 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, CRHR1 RNA expression shows 14,854 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BRCA as cancer lineages where CRHR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRHR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRHR1 survival associations across molecular data types. CRHR1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRHR1 RNA expression–survival associations across cancer types. High CRHR1 expression shows unfavorable associations in UVM, UCEC, LIHC and STAD, but favorable associations in SCLC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CRHR1 RNA expression.
This table summarizes CRHR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CRHR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRHR1 shows lower tumor expression in BRCA, KICH, UCEC and PRAD and higher tumor expression in LUSC and LUAD. The BRCA box plot shows higher CRHR1 RNA expression in normal versus tumor tissue (log2 FC = −0.876, t-test p < 0.001).
This table shows molecular features associated with CRHR1 in patient tissues and cancer cell lines. In patient samples, CRHR1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRHR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
